^
    8ms
    Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Sonnet BioTherapeutics | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    SON-1010
    9ms
    A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers. (PubMed, Front Immunol)
    Its extended half-life leads to a prolonged but controlled IFNγ response, which may be important for tumor control in patients. https://clinicaltrials.gov/study/NCT05408572, identifier NCT05408572.
    Clinical • P1 data • PK/PD data • Journal
    |
    IFNG (Interferon, gamma)
    |
    SON-1010
    over1year
    Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Sonnet BioTherapeutics | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial primary completion date • Metastases
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    SON-1010
    over1year
    Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=165, Not yet recruiting, Sonnet BioTherapeutics | Initiation date: May 2023 --> Aug 2023
    Trial initiation date
    |
    Tecentriq (atezolizumab) • SON-1010
    almost2years
    Clinical development of a novel form of interleukin-12 with extended pharmacokinetics (AACR 2023)
    Two patients were stable at 4 months and 2 had unconfirmed progressive disease; 1 patient remains stable after 8 months on SON-1010 with evidence of tumor regression.SON-1010 may have a positive synergistic effect with an immune checkpoint inhibitor (ICI), particularly with ‘cold’ tumors that over-express SPARC. The next stage of development will be to explore the MTD of SON-1010 in combination with an ICI, then to compare that approach with the standard of care in Phase 2.
    Clinical • PK/PD data
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SPARC (Secreted Protein Acidic And Cysteine Rich) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    SON-1010
    over2years
    Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Sonnet BioTherapeutics
    New P1 trial
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    SON-1010